Lighthouse Pharmaceuticals Secures $12M in Series A to Advance Precision Alzheimer’s Therapeutics

Lighthouse Pharmaceuticals just secured $12M in Series A funding, and the signal coming out of Novato, California isn’t trying to be loud. It’s calibrated. Precise. The kind of move that doesn’t chase attention but earns it from the people who actually read clinical data like it’s scripture.

Novato, California is now home base, and Casey Lynch, CEO, is back in familiar territory, building with intention instead of chasing headlines. This time with a full-stack. Alongside Michael Detke, CMO, and Stephen Dominy, CSO, Lighthouse is advancing LHP588, a second-generation small molecule aimed straight at P. gingivalis, the bacterial culprit they believe has been overstaying its welcome in the Alzheimer’s conversation. You can call it contrarian. You can also call it disciplined. Those two tend to look the same early on.

The bench doesn’t stop there. Joanna Bolger is driving clinical development, Katie Brown is owning CMC, and the advisory layer reads like a who’s who of neurodegeneration. Marwan Sabbagh chairs the board with operators and researchers like Robert Berman, Mark Brody, Jeffrey Cummings, and Lon Schneider in orbit. This isn’t a loose collection of resumes. It’s a system designed to remove guesswork where most programs fail.

Double Point Ventures led the round and didn’t come alone. New and existing investors joined the table, reinforcing that this isn’t momentum built on narrative. It’s conviction built on data. The kind of capital that understands precision medicine only works when you’re ruthless about who you treat. P. gingivalis positive patients only. No noise, just signal.

And let’s not ignore the quiet heavyweight in the room. A $49.2M grant from the National Institute on Aging is already fueling the SPRING Phase 2 trial. That kind of non-dilutive backing does not show up for good storytelling. It shows up for data that earned its seat. The Series A doesn’t validate the science. The science earned the Series A.

Assets reacquired. Molecule refined. Patient population narrowed. Capital aligned. Leadership stacked. Every move points in one direction, and none of it feels accidental. For anyone building in biotech, the takeaway isn’t about volume. It’s about precision. Lighthouse Pharmaceuticals didn’t try to cover the entire map. They picked a specific coordinate and built everything around hitting it clean.